secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001193125-24-041520
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst announces VISION-DMD vamorolone study published in Neurology
---------------------------------------------------------------------

- Peer-reviewed journal Neurology published Santhera's VISION-DMD study on vamorolone (AGAMREE) for DMD.
- Study of 121 boys aged 4 to <7 years showed 6 mg/kg/d vamorolone maintained motor improvements to 48 weeks.
- Vamorolone reversed prednisone-induced bone morbidities including stunted growth and bone biomarker decline.
- Catalyst holds exclusive North American commercialization rights for AGAMREE, already approved in US.
- Results support long-term efficacy and safety profile of vamorolone for Duchenne muscular dystrophy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524041520/0001193125-24-041520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524041520/d706892d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-041520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer